<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04809220</url>
  </required_header>
  <id_info>
    <org_study_id>17779</org_study_id>
    <secondary_id>H9X-JE-GBGQ</secondary_id>
    <nct_id>NCT04809220</nct_id>
  </id_info>
  <brief_title>A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes</brief_title>
  <acronym>AWARD-JPN</acronym>
  <official_title>A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Two Doses of Dulaglutide in Combination With a Single Oral Antihyperglycemic Medication or as Monotherapy in Japanese Patients With Type 2 Diabetes Mellitus (AWARD-JPN: Assessment of Weekly Administration of LY2189265 in Diabetes - JAPAN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of 2 doses of dulaglutide in&#xD;
      Japanese participants with type 2 diabetes. The study duration is approximately 58 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 13, 2021</start_date>
  <completion_date type="Anticipated">February 25, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 12, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Hemoglobin A1c (HbA1c)</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>Change from Baseline in HbA1c</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in HbA1c</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Change from Baseline in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving HbA1c target ≤6.5% and &lt; 7.0%</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Percentage of Participants Achieving HbA1c target ≤6.5% and &lt; 7.0%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting Serum Glucose (FSG)</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Change from Baseline in FSG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 6-point Self-Monitored Blood Glucose (SMBG)</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Change from baseline in 6-point SMBG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Body Weight</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Change from baseline in Body Weight</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">585</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Glucose Metabolism Disorders</condition>
  <condition>Metabolic Disease</condition>
  <condition>Endocrine System Diseases</condition>
  <condition>Hypoglycemic Agents</condition>
  <condition>Type 2 Diabetes Mellitus (T2DM)</condition>
  <arm_group>
    <arm_group_label>1.5 mg Dulaglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 mg Dulaglutide given subcutaneously (SC).&#xD;
Dulaglutide will be given alone or in combination with 1 oral antihyperglycemic medications (OAM).&#xD;
Participants taking DPP-4 inhibitors (DPP-4i) to stop at randomization or if taking other OAM's, then continue taking same dose of OAM during the study period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.75 mg Dulaglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.75 mg Dulaglutide given SC.&#xD;
Dulaglutide will be given alone or in combination with 1 OAM.&#xD;
Participants taking DPP-4i to stop at randomization or if taking other OAM's, then continue taking same dose of OAM during the study period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dulaglutide</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>0.75 mg Dulaglutide</arm_group_label>
    <arm_group_label>1.5 mg Dulaglutide</arm_group_label>
    <other_name>LY2189265</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biguanide (BG)</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>0.75 mg Dulaglutide</arm_group_label>
    <arm_group_label>1.5 mg Dulaglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfonylurea (SU)</intervention_name>
    <description>Pre-administered orally</description>
    <arm_group_label>0.75 mg Dulaglutide</arm_group_label>
    <arm_group_label>1.5 mg Dulaglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alpha-Glucosidase Inhibitors (α-GI)</intervention_name>
    <description>Pre-administered orally</description>
    <arm_group_label>0.75 mg Dulaglutide</arm_group_label>
    <arm_group_label>1.5 mg Dulaglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiazolidinedione (TZD)</intervention_name>
    <description>Pre-administered orally</description>
    <arm_group_label>0.75 mg Dulaglutide</arm_group_label>
    <arm_group_label>1.5 mg Dulaglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glinides (GLN)</intervention_name>
    <description>Pre-administered orally</description>
    <arm_group_label>0.75 mg Dulaglutide</arm_group_label>
    <arm_group_label>1.5 mg Dulaglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium-glucose cotransporter type 2 inhibitors (SGLT2i)</intervention_name>
    <description>Pre-administered orally</description>
    <arm_group_label>0.75 mg Dulaglutide</arm_group_label>
    <arm_group_label>1.5 mg Dulaglutide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants with type 2 diabetes (T2D) ≥ 6 months according to the World Health&#xD;
             Organization (WHO) classification.&#xD;
&#xD;
          -  Treated with stable doses of a single OAM for at least 8 weeks prior to screening; the&#xD;
             dose must be more than or equal to minimum maintenance dose.&#xD;
&#xD;
          -  Have the following HbA1c result at screening.&#xD;
&#xD;
               -  Participants taking DPP-4i: ≥7.5% and ≤9.5%,&#xD;
&#xD;
               -  Participants taking another OAM: ≥8.0% and ≤10.0%&#xD;
&#xD;
          -  Stable body weight for at least 8 weeks prior to screening or not changed by more than&#xD;
             5 % in the past 8 weeks&#xD;
&#xD;
          -  Have a body mass index (BMI) ≥18.5 kilogram/square meter (kg/m²) and &lt;35 kg/m² at Day&#xD;
             1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have type 1 diabetes (T1D)&#xD;
&#xD;
          -  Have a history of ≥1 episode of ketoacidosis or hyperosmola state/coma&#xD;
&#xD;
          -  Have had any myocardial infarction (MI), heart failure or cerebrovascular accident&#xD;
             (stroke)&#xD;
&#xD;
          -  Have a known clinically significant gastric empty abnormality&#xD;
&#xD;
          -  Have acute or chronic hepatitis&#xD;
&#xD;
          -  Have had chronic or acute pancreatitis&#xD;
&#xD;
          -  Have any self or family history of type 2A or type 2B multiple endocrine neoplasia in&#xD;
             the absence of known C-cell hyperplasia&#xD;
&#xD;
          -  Have any self or family history of medullary C-cell hyperplasia, focal hyperplasia, or&#xD;
             carcinoma (including sporadic, familial, or part of Multiple endocrine neoplasia (MEN)&#xD;
             2A or 2B syndrome)&#xD;
&#xD;
          -  Have evidence of significant, active autoimmune abnormality&#xD;
&#xD;
          -  Have evidence of significant, uncontrolled endocrine abnormality&#xD;
&#xD;
          -  Have active or untreated malignancy, or have been in remission from clinically&#xD;
             significant malignancy (other than basal cell or squamous cell skin cancer) for less&#xD;
             than 5 years&#xD;
&#xD;
          -  Have any hematologic condition that may interfere with HbA1c measurement&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon- Fri 9 AM- 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nakayama Clinic</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>456-0058</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Mikihiro Nakayama</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tosaki Clinic for Diabetes and Endocrinology</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>468-0009</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Takahiro Tosaki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kashiwa City Hospital</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-0825</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Takeshi Inazawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kobari General Clinic</name>
      <address>
        <city>Noda</city>
        <state>Chiba</state>
        <zip>278-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Fumihiko Hojo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nippon Kokan Fukuyama Hospital</name>
      <address>
        <city>Fukuyama</city>
        <state>Hiroshima</state>
        <zip>721-0927</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Tomomi Hakoda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yamagata Naika Clinic</name>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido</state>
        <zip>078-8234</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Kazuo Yamagata</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hasegawa Medical Clinic</name>
      <address>
        <city>Chitose</city>
        <state>Hokkaido</state>
        <zip>066-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Atsushi Hasegawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yuri Ono Clinic</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Yuri Ono</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manda Memorial Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0062</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Hidenori Bando</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miyanosawa Clinic of Internal Medicine and Cardiology</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>063-0826</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Shin-ichiro Satoh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Takabe Diabetes Clinic</name>
      <address>
        <city>Himeji</city>
        <state>Hyogo</state>
        <zip>670-0837</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Michinori takabe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nakamoto Internal Medicine Clinic</name>
      <address>
        <city>Mito</city>
        <state>Ibaraki</state>
        <zip>310-0826</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Shinya Nakamoto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nishiyamadou Keiwa Hospital</name>
      <address>
        <city>Naka</city>
        <state>Ibaraki</state>
        <zip>311-0133</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Sumiko Hasumi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hayashi Diabetes Internal Medicine Clinic</name>
      <address>
        <city>Chigasaki</city>
        <state>Kanagawa</state>
        <zip>253-0044</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Tsutomu Hayashi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Takai Internal Medicine Clinic</name>
      <address>
        <city>Kamakura-shi</city>
        <state>Kanagawa</state>
        <zip>247-0056</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Masahiko Takai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shonan Takai Clinic</name>
      <address>
        <city>Kamakura</city>
        <state>Kanagawa</state>
        <zip>247-0055</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Kuninobu Takai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yamagishi Clinic Sagamiono</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>252-0303</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>TAKAHIRO YAMAGISHI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Yuga Tsuruma Kaneshiro Diabetes Clinic</name>
      <address>
        <city>Yamato-shi</city>
        <state>Kanagawa</state>
        <zip>242-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Taro Asakura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seiryo Internal Medicine</name>
      <address>
        <city>Iwanuma</city>
        <state>Miyagi</state>
        <zip>989-2451</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Hiroshi Haga</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gibo Hepatology Clinic</name>
      <address>
        <city>Matsumoto</city>
        <state>Nagano</state>
        <zip>399-0036</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Yukio Gibo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shiraiwa Medical Clinic</name>
      <address>
        <city>Kashiwara</city>
        <state>Osaka</state>
        <zip>582-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Toshihiko Shiraiwa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sugiura Internal Medicine Clinic</name>
      <address>
        <city>Soka</city>
        <state>Saitama</state>
        <zip>340-0034</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Tatsushi Sugiura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seiwa Clinic</name>
      <address>
        <city>Adachi-ku</city>
        <state>Tokyo</state>
        <zip>120-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Hideki Tanaka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokyo-Eki Center-building Clinic</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>103-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Arihiro Kiyosue</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Chiseikai Tokyo Center Clinic</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>103-0028</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Hirotaka Nagashima</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fukuwa Clinic</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Yasushi Fukushima</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hachioji Diabetes Clinic</name>
      <address>
        <city>Hachioji</city>
        <state>Tokyo</state>
        <zip>192-0083</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Naoyuki Yamamoto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minamino Cardiovascular Hospital</name>
      <address>
        <city>Hachioji</city>
        <state>Tokyo</state>
        <zip>192-0918</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Yoshiki Hata</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nomura Clinic</name>
      <address>
        <city>Itabashi</city>
        <state>Tokyo</state>
        <zip>173-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Kazushi Nomura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yutenji Medical Clinic</name>
      <address>
        <city>Meguro-ku</city>
        <state>Tokyo</state>
        <zip>153-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Kotaro Shimokawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kanno Naika</name>
      <address>
        <city>Mitaka</city>
        <state>Tokyo</state>
        <zip>181-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Kazuo Kanno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Futata Tetsuhiro Clinic</name>
      <address>
        <city>Fukuoka</city>
        <zip>810-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Dai Shimono</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yoshimura Clinic</name>
      <address>
        <city>Kumamoto</city>
        <zip>861-8039</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Ryohei Yoshimura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jinnouchi Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>862-0976</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Hideaki Jinnouchi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heiwadai Hospital</name>
      <address>
        <city>Miyazaki</city>
        <zip>880-0034</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Shuji Nakamura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ota Diabetes Internal Medicine Clinic</name>
      <address>
        <city>Nagano</city>
        <zip>380-0802</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Yasuharu Ota</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abe Clinic</name>
      <address>
        <city>Oita</city>
        <zip>870-0039</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Katsushige Abe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kitada Clinic</name>
      <address>
        <city>Osaka</city>
        <zip>538-0044</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Hirokazu Kitada</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Tomoaki Morioka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanko Clinic</name>
      <address>
        <city>Osaka</city>
        <zip>559-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Shoichi Kitano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 1, 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dulaglutide</mesh_term>
    <mesh_term>Biguanides</mesh_term>
    <mesh_term>2,4-thiazolidinedione</mesh_term>
    <mesh_term>Glycoside Hydrolase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

